Cost analysis of Wilson's disease in Italy: a retrospective cohort studyDIGESTIVE AND LIVER DISEASEIF3.82024-02-010PRE
Economic aspects in the treatment of schizophrenia in Italy: Cost consequences of an early long-acting injectable anti-psychotics (lais) approachEUROPEAN PSYCHIATRYIF6.72020-03-230PREAI
MENTAL DISORDERS AND MAJOR DEPRESSION: THE ECONOMIC ANALYSIS OF SOCIAL SECURITY COSTS IN ITALYVALUE IN HEALTHIF62018-10-010OAAI
SECONDARY PREVENTION FOR CARDIOVASCULAR DISEASE: DEFINITION OF POPULATION AND EVALUATION OF OUTCOMES USING REAL WORLD DATAVALUE IN HEALTHIF62018-10-010OAAI
ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE: A REAL-WORLD-BASED ANALYSIS FROM PITER DATAVALUE IN HEALTHIF62018-10-010OAAI
HPV9-RELATED DISEASES: THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM IN ITALYVALUE IN HEALTHIF62018-10-010OAAI
BUDGET IMPACT ANALYSIS OF THE USE OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA IN ITALYVALUE IN HEALTHIF62018-10-010OAAI
ESTIMATES OF KIDNEY STONES COSTS. AN ANALYSIS OF CLINICAL AND ADMINISTRATIVE DATA TO MEASURE THE BURDEN OF KIDNEY STONES IN ITALYVALUE IN HEALTHIF62018-10-010OAAI
HTA OF ARTIFICIAL URINARY SPHINCTER (AUS) FOR THE TREATMENT OF SEVERE MALE POST-PROSTATECTOMY INCONTINENCE IN ITALYVALUE IN HEALTHIF62018-10-011OAAI
MULTIPLE SCLEROSIS AND WORKABILITY IN ITALY: THE ECONOMIC EFFECT OF NATALIZUMAB ON THE ABILITY TO WORKVALUE IN HEALTHIF62018-10-010OAAI
COST ESTIMATE OF IMMUNE-RELATED ADVERSE REACTIONS ASSOCIATED WITH INNOVATIVE TREATMENTS OF METASTATIC MELANOMAVALUE IN HEALTHIF62018-10-010OAAI
INFLAMMATORY BOWEL DISEASE AND THE COST FOR SOCIAL SECURITY SYSTEM: ESTIMATING THE PREVALENCE AND THE DISABILITY BURDEN AMONG THE ITALIAN WORKERVALUE IN HEALTHIF62018-10-010OAAI
BUDGET IMPACT ANALYSIS OF INHALED LOXAPINE FOR THE MANAGEMENT OF PSYCHOMOTOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER IN ITALYVALUE IN HEALTHIF62018-10-010OAAI
THE ECONOMIC CONSEQUENCES OF BENEFITS OF DELAYED-RELEASE DIMETHYL FUMARATE TREATMENT VERSUS BETA INTERFERONS AND GLATIRAMER ACETATE ON ABILITY TO WORK OF MULTIPLE SCLEROSIS PATIENTS IN ITALYVALUE IN HEALTHIF62018-10-011OAAI
Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF重组FSH加重组LH与人绝经期促性腺激素对接受IVF的妇女进行控制性卵巢刺激的概率成本-效果分析REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGYIF4.72018-07-1813OAAI
ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVEVALUE IN HEALTHIF62018-05-010OAAI
PROBABILISTIC COST-UTILITY ANALYSIS OF PERGOVERIS IN WOMEN PATIENTS UNDERGOING IVFVALUE IN HEALTHIF62017-10-011OAAI
A COST EFFECTIVENESS ANALYSIS OF SEASONAL QUADRIVALENT INFLUENZA VACCINE IN ITALY USING A STATIC MODELVALUE IN HEALTHIF62017-10-011OAAI
COST PER RESPONSE FOR ABATACEPT COMPARED WITH ADALIMUMAB IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON ANTI-CITRULLINATED PROTEIN ANTIBODY TITRES IN ITALYVALUE IN HEALTHIF62017-10-010OAAI